Price
Target price
€51.34
€51.34
0.430%
0.22
0.430%
€60.19
09:45 / Tradegate
WKN: A0DLHS / Symbol: HALO / Name: Halozyme / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Halozyme Therapeutics Inc. Stock
Halozyme Therapeutics Inc. gained 0.430% compared to yesterday.
We see a rather positive sentiment for Halozyme Therapeutics Inc. with 20 Buy predictions and 1 Sell predictions.
As a result the target price of 60 € shows a slightly positive potential of 16.87% compared to the current price of 51.34 € for Halozyme Therapeutics Inc..
For the coming years our community has positive and negative things to say abot the Halozyme Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Expected dividend yield" there were negative voices in the community.
Pros and Cons of Halozyme Therapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
B****
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Halozyme Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc. | 0.430% | 4.412% | 14.516% | -0.234% | 11.860% | 6.834% | 114.520% |
| Ironwood Pharmaceuticals | 2.010% | 2.256% | 14.286% | -89.206% | -83.810% | -94.347% | -91.226% |
| Novocure Ltd | 0.020% | -29.023% | -35.990% | -48.775% | -66.181% | -85.195% | -82.950% |
| Iovance Biotherapeutics Inc. | -6.570% | -5.380% | 74.896% | -69.700% | -63.329% | -77.793% | -89.595% |
Comments
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $72.00 price target on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) was downgraded by analysts at Leerink Partners from a "market perform" rating to an "underperform" rating. They now have a $47.00 price target on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $72.00 price target on the stock.
Show more
Ratings data for HALO provided by MarketBeat